Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 88Neoplasms 6HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Locally Advanced Breast Cancer 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × pertuzumab × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡